ArticleAmerican journal of cancer research2025
Correlation and predictive modeling of serum exosomal miRNAs and serological biomarkers for lymph node metastasis in gastric cancer.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the predictive potential of serum exosomal microRNAs (miRNAs) and traditional serological biomarkers for lymph node metastasis in gastric cancer and to assess their applicability in clinical practice.
methodsThis retrospective study included 845 gastric cancer patients treated between January 2020 and December 2023, as the training cohort. Patients were stratified into lymph node-positive (n = 231) and lymph node-negative (n = 614) groups based on postoperative pathological evaluation. Serum exosomal miRNAs and conventional serological biomarkers were quantified and compared between groups. Multivariate logistic regression analysis was conducted to identify independent predictors. Model performance was validated using an independent test cohort comprising 277 patients (74 lymph node-positive, 203 lymph node-negative).
resultsPatients with lymph node metastasis exhibited significantly elevated expression of miR-21, miR-20a, miR-27a, and miR-106a. Serological markers that were significantly higher in the lymph node positive group included carbohydrate antigen 724, carcinoembryonic antigen, hepatocyte growth factor, vascular endothelial growth factor, interleukin-6, and circulating cell-free DNA (all P < 0.05). A combined predictive model integrating both miRNA and serological data demonstrated strong diagnostic performance, with an area under the curve of 0.816 in the training cohort and 0.817 in the validation cohort.
conclusionSerum exosomal miRNAs and serological biomarkers are significantly associated with lymph node metastasis in gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.